Protocol Ledger

NCT05700591 · Phase III · COMPLETED

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

Interventional Phase III clinical trial protocol NCT05700591 sponsored by Tasly Biopharmaceuticals Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-01-29 Enrollment: 1,552 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05700591
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,552 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05700591
Protocol FieldVerified Registry Value
NCT IdentifierNCT05700591
Consolidated Lead SponsorTasly Biopharmaceuticals Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,552 participants (ACTUAL)
Registered Start Date2023-01-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI